{"nctId":"NCT02148445","briefTitle":"Smoking Cessation Versus Long-term Nicotine Replacement Among High-risk Smokers","startDateStruct":{"date":"2014-05"},"conditions":["Smoking","Pulmonary Disease, Chronic Obstructive","Tobacco Use Disorder"],"count":398,"armGroups":[{"label":"Standard Smoking Cessation","type":"ACTIVE_COMPARATOR","interventionNames":["Other: Standard Smoking Cessation","Drug: Nicotine replacement therapy"]},{"label":"Extended Nicotine Replacement Therapy","type":"EXPERIMENTAL","interventionNames":["Other: Extended Nicotine Replacement Therapy","Drug: Nicotine replacement therapy"]}],"interventions":[{"name":"Standard Smoking Cessation","otherNames":[]},{"name":"Extended Nicotine Replacement Therapy","otherNames":[]},{"name":"Nicotine replacement therapy","otherNames":["nicotine patch, nicotine gum, nicotine lozenge"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 18 years of age or older\n* Physician-diagnosed COPD\n* Smoke 5 or more cigarettes/day\n* Smoke cigarettes on 25 or more of the last 30 days\n* Speak either English or Spanish\n* Willing to take nicotine replacement therapy for up to 1 year and participate in study procedures\n\nExclusion Criteria:\n\n* Reside in a facility that does not allow smoking\n* Don't have an address and telephone\n* Unstable cardiac condition (e.g. unstable angina or myocardial infarction in the past 30 days)\n* Pregnant or breastfeeding\n* Terminal illness with less than 12 month life expectancy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Smoking Abstinence (Point Prevalent)","description":"7-day point prevalent abstinence at 12 months, confirmed by exhaled CO \\<=10","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Sustained Abstinence","description":"6 month sustained abstinence as measured by self-report at 6 and 12 months and confirmed by CO at 6 and 12 months. Participants who were confirmed as non-smokers by carbon monoxide (CO) at both Month 6 and Month 12 were considered to have \"6-month sustained abstinence.\"","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Quit Attempts","description":"Number of self-reported quit attempts over one year. At Month 3 and Month 6, participants reported the number of quit attempts in the last 3 months. At Month 12, participants reported the number of quit attempts in the last 6 months.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":"6.54"},{"groupId":"OG001","value":"3.7","spread":"5.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":"6.86"},{"groupId":"OG001","value":"4.8","spread":"8.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":"8.59"},{"groupId":"OG001","value":"6.2","spread":"11.31"}]}]}]},{"type":"SECONDARY","title":"Average Cigarettes Per Day","description":"Average number of cigarettes per day over one year. Participants were asked at Month 3, Month 6, and Month 12 \"During the past 7 days, on those days that you smoked, what was the average number of cigarettes or little cigars smoked per day?\"","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","spread":"8.64"},{"groupId":"OG001","value":"10.5","spread":"8.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":"8.52"},{"groupId":"OG001","value":"9.1","spread":"9.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","spread":"7.84"},{"groupId":"OG001","value":"8.1","spread":"8.33"}]}]}]},{"type":"SECONDARY","title":"Carbon Monoxide Exposure","description":"Carbon monoxide (CO) exposure over 12 months. At Month 3, Month 6, and Month 12, participants completed an expired carbon monoxide laboratory test, which measured CO in parts per million.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.0","spread":"12.62"},{"groupId":"OG001","value":"17.4","spread":"13.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.6","spread":"11.85"},{"groupId":"OG001","value":"15.4","spread":"12.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.5","spread":"11.14"},{"groupId":"OG001","value":"13.8","spread":"11.14"}]}]}]},{"type":"SECONDARY","title":"Carcinogen Exposure","description":"Creatinine-adjusted NNAL (4-(methylnitrosamino)-1-(3)pyridyl-1-butanol)) exposure over 12 months. At Month 3, Month 6, and Month 12, participants provided a urine sample that was used to assess their level of urinary creatinine and NNAL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"279.0","spread":"353.42"},{"groupId":"OG001","value":"320.1","spread":"350.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"178.2","spread":"221.26"},{"groupId":"OG001","value":"186.0","spread":"236.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"190.4","spread":"233.22"},{"groupId":"OG001","value":"183.5","spread":"223.94"}]}]}]},{"type":"SECONDARY","title":"Respiratory Function","description":"Change in respiratory function, as measured by spirometry (FEV1), at 12 months post-randomization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.4","spread":"19.25"},{"groupId":"OG001","value":"56.8","spread":"19.78"}]}]}]},{"type":"SECONDARY","title":"Respiratory Symptoms","description":"Respiratory symptoms as measured by the COPD Assessment Test (CAT) respiratory questionnaire. Participants completed this 8-item assessment at Month 3, Month 6, and Month 12. Scores range from 0 to 40, with higher levels indicating higher impact of COPD on well-being and daily life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.8","spread":"9.25"},{"groupId":"OG001","value":"19.3","spread":"8.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.9","spread":"9.48"},{"groupId":"OG001","value":"18.1","spread":"8.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.5","spread":"9.33"},{"groupId":"OG001","value":"18.2","spread":"9.37"}]}]}]},{"type":"SECONDARY","title":"Respiratory-related Hospital Visits","description":"Number of respiratory-related hospital admissions and emergency room visits. Participants were asked how many times they had visited the ED or were admitted to the hospital for respiratory-related problems at Month 3, Month 6, and Month 12","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"176","spread":null},{"groupId":"OG001","value":"169","spread":null}]},{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"15","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"152","spread":null},{"groupId":"OG001","value":"154","spread":null}]},{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"24","spread":null}]},{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"157","spread":null},{"groupId":"OG001","value":"153","spread":null}]},{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"20","spread":null}]},{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Cardiac-related Hospital Visits","description":"Number of cardiac-related hospital admissions and emergency room visits. Participants were asked how many times they had visited the ED or were admitted to the hospital for cardiac-related problems at Month 3, Month 6, and Month 12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"181","spread":null},{"groupId":"OG001","value":"185","spread":null}]},{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"6","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"171","spread":null},{"groupId":"OG001","value":"180","spread":null}]},{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"4","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"175","spread":null},{"groupId":"OG001","value":"167","spread":null}]},{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"12","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"7-day Abstinence","description":"Self-reported and biochemically verified 7-day abstinence. Participants were asked at Month 3, Month 6, and Month 12, \"Have you smoked any cigarettes or little cigars, even a puff, in the past 7 days?\" They also completed an exhaled carbon monoxide lab test at Month 3, 6 and 12. Biochemical verification= exhaled CO \\<=10 ppm. Month 12 biochemically verified abstinence is the primary outcome, and is not reported in this table.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Cotinine","description":"Cotinine over 12 months, adjusted for creatinine. At Month 3, Month 6, and Month 12, participants provided a urine sample that was used to assess their level of urinary creatinine and cotinine.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2652.5","spread":"2675.18"},{"groupId":"OG001","value":"3378.1","spread":"3182.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2390.7","spread":"2842.07"},{"groupId":"OG001","value":"3342.3","spread":"3282.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2159.0","spread":"2989.46"},{"groupId":"OG001","value":"2363.7","spread":"2988.16"}]}]}]},{"type":"SECONDARY","title":"Average Cigarettes Per Day (Continued Smokers Only)","description":"Average number of cigarettes per day over one year, among continued smokers. All participants were asked \"During the past 7 days, on those days that you smoked, what was the average number of cigarettes smoked per day?\" at Month 3, Month 6, and Month 12. This analysis looks at the number of cigarettes per day among participants who were still smoking.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.7","spread":"8.84"},{"groupId":"OG001","value":"11.4","spread":"8.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.1","spread":"8.62"},{"groupId":"OG001","value":"9.9","spread":"9.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.7","spread":"7.64"},{"groupId":"OG001","value":"9.3","spread":"8.27"}]}]}]},{"type":"SECONDARY","title":"Carbon Monoxide Exposure (Continued Smokers Only)","description":"Carbon monoxide (CO) exposure over 12 months. At Month 3, Month 6, and Month 12, participants completed an expired carbon monoxide laboratory test, which measured CO in parts per million. This analysis looks at CO among those continuing to smoke.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.4","spread":"12.56"},{"groupId":"OG001","value":"18.8","spread":"13.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.0","spread":"11.68"},{"groupId":"OG001","value":"17.0","spread":"12.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.4","spread":"10.57"},{"groupId":"OG001","value":"15.8","spread":"10.73"}]}]}]},{"type":"SECONDARY","title":"Carcinogen Exposure (Continued Smokers Only)","description":"Creatinine-adjusted NNAL (4-(methylnitrosamino)-1-(3)pyridyl-1-butanol)) exposure over 12 months. At Month 3, Month 6, and Month 12, participants provided a urine sample that was used to assess their level of urinary creatinine and NNAL. This analysis looks at NNAL among continuing smokers only.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"314.6","spread":"373.23"},{"groupId":"OG001","value":"337.6","spread":"363.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"219.8","spread":"236.30"},{"groupId":"OG001","value":"217.1","spread":"251.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"257.0","spread":"234.83"},{"groupId":"OG001","value":"247.5","spread":"230.64"}]}]}]},{"type":"SECONDARY","title":"Cotinine (Continued Smokers Only)","description":"Cotinine over 12 months, adjusted for creatinine. At Month 3, Month 6, and Month 12, participants provided a urine sample that was used to assess their level of urinary creatinine and cotinine. This analysis looks at NNAL among continuing smokers only.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2771.2","spread":"2774.24"},{"groupId":"OG001","value":"3305.8","spread":"2859.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2850.7","spread":"2645.50"},{"groupId":"OG001","value":"3502.2","spread":"2978.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2733.9","spread":"2532.32"},{"groupId":"OG001","value":"2782.7","spread":"2583.60"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":198},"commonTop":["Local skin reactions","Upper GI symptoms","Sleep Disturbance","Oral discomfort","Change in affect or state of arousal"]}}}